The results of the trials of Aplidin as a treatment against the coronavirus re-launch investor optimism.
The biotechnology of the Spanish stock index, PharmaMar launched in a new rally among expectant investors to the results of the new tests of Aplidin as a treatment against the coronavirus. The hikes accelerate this Friday to pulverize historical records when communicating that the trials have produced “positive results” for both safety and efficacy.
Since last March PharmaMar surprised to announce that its antitumor drug Aplidin could be effective in treating coronavirus, biotech investors have had a possible additional catalyst to accelerate the rally of best value of the entire Spanish Stock Market in 2020.
At the close of yesterday accumulated a 205% revaluation, and today a new push. PharmaMar is once again leading the Ibex rises, with advances that at times exceed 10%, in its best session since joining the Ibex. Their shares thus pulverize their historical records, by far exceeding the maximum of 135.16 euros registered last July. On this day, he breaks the barrier of 140 euros. In this way, your Market value thus reaches 2,600 million euros.
What is behind the rally?
In a statement sent to the CNMV, the company states that “its Aplicov-PC clinical trial with Aplidin (plitidepsin) for the treatment of adult patients with Covid-19, who require hospital admission, has met the primary safety and secondary efficacy objectives“.
The biopharmaceutical details that “the study has shown a marked reduction in viral load in patients between days 4 and 7 after the start of treatment, so that the mean reduction in viral load on day 7 was 50%, and 70% on day 15. More than 90% of the patients included in the trial had medium or high viral loads at the beginning “.
Studies reveal the improvements achieved in the longer term. “80.7% of the patients have been discharged from hospital on or before the 15th day of hospitalization, and 38.2% before the 8th” and “on day 30, in the scheduled clinical visit, none of the patients treated with plitidepsin had developed symptoms or signs derived from Covid-19 infection “.
The “positive results” of the study “in this first group of patients” have led PharmaMar to request and obtain from the Spanish Agency for Medicines and Health Products (AEMPS) the “authorization for an extension of the patient cohort”.
With the data obtained, which will be presented “in scientific congresses and / or in a prestigious medical journal”, PharmaMar advances that “the company will, in the next few days, begin conversations with the regulatory agencies to define the next study of phase III Plitidepsin Registry in COVID-19 Patients Requiring Hospitalization “.
Aplidin vs remdesivir
The publication of the trial results coincides with the latest studies questioning the efficacy of Gilead’s remdesivir as a treatment against Covid-19. According to the WHO, the drug does not achieve significant results in preventing mortality from coronavirus.
Precisely months ago PharmaMar established a comparison of the results of the Aplidin trials with those of remdesivir. Last July it surprised the market by announcing that in certain cell models Aplidin has “shown an antiviral activity between 2,400 and 2,800 times greater than remdesivir”.
In today’s statement PharmaMar avoids comparisons with Gilead’s remdesivir, Although it could give more details in the press conference it has called for next Monday, at 11 am, in order to report the results, and in which the principal investigators of the trial will participate. The press conference “can be accessed electronically”, according to the company.